Open Nav

Genekam Biotechnology AG

  • Sudhir Bhatia, Genekam Biotechnology AG

Expand in USA and make an IPO to serve world with best quality medical soluitions

  • Date:Thursday, October 18
  • Time:11:00 AM - 11:15 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Genekam is developing most advanced and cost effective solutions for virology (pandemic viruses like influenza, ebola, lassa, SARS as well as mosquito borne pathogens like Zika viruses, West nile virus, Dengue virus, Usutu virus, Yellow fever etc). It focuses on immunology particularly on B-cells to create next generation solutions like human therapeutic antibodies and small molecules. It has developed around 700 different assays for different pathogens. Genekam may be the only company in the world carrying largest collections of assays to detect any influenza virus ranging from H1 to H15 and N1 to N10 circulating around the world. Now it is focusing on development of therapeutic molecules and antibodies to develop the possible treatment for influenza viruses. Its mission is to create a vaccine with zero side effects. Other areas, where Genekam focuses are magnetic beads applications and development of tools to make genetherapy economical and safer.
  • Company Website:www.genekam.de
  • Company HQ City:Duisburg
  • Company HQ Country:Germany
  • CEO/Top Company Official:Sudhir Bhatia
  • Year Founded:1999
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development :Many products under development
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :10
  • Additional Information/Comments:Genekam Biotechnology AG is developing and manufacturing its products in Germany. It has around 30 in viro diagnostic tests with CE-IVD. Among these tests, some of most important ones are for H5N1, Zika, Yellow fever virus, Dengue virus and H1N1 (2009 Strain). Its products are being sold in many countries around the world. Genekam covers a number of biodefence pathogens like Anthrax, Tularemia, Clostridium etc. It has developed its own tools to accelerate the development of therapeutic molecules. Genekam has two small molecules, which has shown in vitro studies that they are effective against Zika viruses and shows almost no toxicity. It has developed some potential therapeutic antibodies and 3D stem cells technology, which may be basis of a number of new innovations. Genekam is working on patents to be filled. Many of the products developed may qualify for CLIA in USA and also for FDA approvals.
  • Previous and Current Investors:Non
  • Size of Last Investment Round:Zero
  • Total Amount Raised to Date, In All Rounds:Zero (Genekam has funded its research itself till today)
Speakers
Sudhir Bhatia
Genekam Biotechnology AG
Back